Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized extension study of votoplam in Huntington's disease
2023-504628-24-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing Votoplam with Placebo (2 arms). Primary endpoints: Safety profile as characterized by TEAEs, laboratory abnormalities, vital signs, physical examination, C-SSRS and Evaluate blood tHTT protein levels over time. Planned start Sep 2023; status: authorised.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2023-504628-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504628-24-00.